Stockscreener 앱 받기
73.67
7.93%
5.41
시간 외 거래:
71.24
-2.43
-3.30%
전일 마감가:
$68.26
열려 있는:
$67.53
하루 거래량:
1.87M
Relative Volume:
2.05
시가총액:
$3.13B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-24.58
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
+50.44%
1개월 성능:
+50.90%
6개월 성능:
+48.29%
1년 성능:
+76.20%
1일 변동 폭
$66.60
$73.96
1주일 범위
$65.00
$73.97
52주 변동 폭
$36.61
$73.97
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
73.67 | 3.13B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Soleno therapeutics SVP sells $265,156 in stock - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 Shares - MarketBeat
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod By Investing.com - Investing.com South Africa
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod - Investing.com India
High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st
Soleno Therapeutics CEO sells $35.3 million in stock By Investing.com - Investing.com Philippines
Soleno Therapeutics exec sells shares worth $9.5 million By Investing.com - Investing.com Australia
Soleno therapeutics director Matthew Pauls sells $424,797 in stock By Investing.com - Investing.com Canada
Soleno Therapeutics CCO sells shares worth $2.48m By Investing.com - Investing.com South Africa
Soleno Therapeutics Executives and Director Sell Shares - TradingView
Soleno Therapeutics CCO sells shares worth $2.48m - Investing.com
Soleno therapeutics director Matthew Pauls sells $424,797 in stock - Investing.com
Soleno Therapeutics CFO sells $4.88 million in stock - Investing.com
Soleno Therapeutics exec sells shares worth $9.5 million - Investing.com India
Soleno Therapeutics CEO sells $35.3 million in stock - Investing.com
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock - Investing.com
Soleno Therapeutics Executives Sell Shares - TradingView
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock - Investing.com Australia
Soleno stock price target raised to $100 at H.C. Wainwright By Investing.com - Investing.com South Africa
Soleno stock price target raised to $100 at H.C. Wainwright - Investing.com
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock By Investing.com - Investing.com South Africa
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment - Markets Insider
Mid Cap Stocks To ResearchMarch 27th - MarketBeat
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? - Insider Monkey
10 Stocks Outperform Broader Market Last Week - Insider Monkey
Soleno Therapeutics (NASDAQ:SLNO) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
Vivo opportunity sells $124 million in Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? - MSN
Guggenheim raises Soleno Therapeutics stock target to $81 By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Soleno Therapeutics! - TipRanks
Vivo opportunity sells $124 million in Soleno Therapeutics stock - Investing.com
Stifel raises Soleno stock target to $108 after FDA approval By Investing.com - Investing.com South Africa
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR - PR Newswire
Stifel raises Soleno stock target to $108 after FDA approval - Investing.com
Soleno Therapeutics price target raised to $108 from $74 at Stifel - TipRanks
FDA Approves First Therapy To Treat Hyperphagia in Prader-Willi Syndrome - Technology Networks
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Insider Monkey
Soleno Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
FDA Greenlights Soleno Therapeutics’ VYKAT XR for PWS Hyperphagia - geneonline.com
Oppenheimer lifts Soleno Therapeutics stock target to $105 By Investing.com - Investing.com Canada
Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease - Mugglehead
Biotech Zooms Into Breakout Zone On Hard-Fought Approval - Investor's Business Daily
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars - BioWorld MedTech
Drugmaker Soleno Soars on Approval to Treat Never Ending Hunger - Bloomberg
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SLNO) - Seeking Alpha
Soleno wins FDA approval for Prader-Willi hyperphagia treatment - Yahoo
Soleno Shares Are Up Today: What's Going On? - Benzinga
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome - Pharmaceutical Executive
Baird Raises Soleno Therapeutics' Price Target to $102 From $72, Outperform Rating Maintained - Marketscreener.com
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment - RagingBull
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):